BUSINESS

Daiichi Sankyo Joins Portola’s Factor Xa Antidote Consortium in Japan

April 6, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Daiichi Sankyo has inked a collaboration agreement with Portola Pharmaceuticals to develop the US firm’s andexanet alfa in Japan as an antidote for its factor Xa inhibitor edoxaban, the two companies said. This follows Portola’s recent agreements with Bristol-Myers Squibb,…

To read the full story

BMS, Pfizer to Codevelop Factor Xa Antidote in Japan
February 5, 2016

BUSINESS

Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
May 12, 2026
Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
May 12, 2026
Teijin to Offload Legacy Drug Portfolio as It Speeds Up Pivot to Rare Diseases
May 12, 2026
Keytruda Extends Run as Japan’s Best-Selling Drug in April: Encise
May 12, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…